ISRCTN95382621已完成未知
Impact of dapagliflozin on echocardiographic parameters in patients with heart failure and reduced ejection fraction
Mouloud Mammeri University of Tizi-Ouzou0 个研究点目标入组 43 人开始时间: 2022年7月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 43
研究概览
简要总结
2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36096950/ (added 09/05/2023)
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •Patients with HFrEF<40% in NYHA stage II to IV, who presented to our department during the recruitment period
排除标准
- •Type 1 diabetes
研究者
相似试验
招募中
2 期
Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKDChronic Kidney DiseasesNCT05359263Tor Biering-Sørensen222
尚未招募
3 期
Effect of Empagliflozin on clinical and echocardiographic parameters in patient with reduced LVEF heart failureHeart failureIRCT20210809052117N1Shahid Beheshti University of Medical Sciences44
进行中（未招募）
1 期
Effects of Dapagliflozin on cardiac deformation and clinical outcomes in heart failure with reduced and mildly reduced ejection fractioheart failure with left ventricular ejection fraction <50%MedDRA version: 20.0Level: LLTClassification code 10024102Term: Left cardiac failureSystem Organ Class: 100000004849EUCTR2021-005394-66-ITAZIENDA OSPEDALIERA UNIVERSITARIA SENESE88
已完成
3 期
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular EventsDiabetes Mellitus, Non-Insulin-DependentHigh Risk for Cardiovascular EventNCT01730534AstraZeneca17,190
招募中
3 期
Effect of Dapagliflozin for Epicardial Adipose Tissue Reduction in Patients with Asymptomatic Heart FailureHeart failureAsymptomatic heart failureJPRN-jRCT1051220025Tanaka Atsushi230